Celgene Co. (NASDAQ:CELG) Director James J. Loughlin sold 23,466 shares of Celgene stock in a transaction that occurred on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
CELG traded up $1.96 during trading on Monday, reaching $89.87. 10,874,374 shares of the company’s stock were exchanged, compared to its average volume of 13,986,993. The company has a debt-to-equity ratio of 4.06, a quick ratio of 1.99 and a current ratio of 2.13. Celgene Co. has a fifty-two week low of $58.59 and a fifty-two week high of $97.43. The firm has a market capitalization of $61.66 billion, a PE ratio of 11.81, a P/E/G ratio of 0.41 and a beta of 1.72.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 125.35%. The firm had revenue of $4.04 billion during the quarter, compared to analyst estimates of $3.98 billion. During the same quarter in the previous year, the business earned $2.00 EPS. Equities analysts forecast that Celgene Co. will post 10.01 EPS for the current year.
A number of research firms have recently issued reports on CELG. Jefferies Financial Group cut shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a research note on Friday, February 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $100.00 target price on shares of Celgene in a research note on Thursday, January 31st. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 target price for the company in a research note on Wednesday, January 23rd. Robert W. Baird upgraded shares of Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Friday, January 4th. Finally, BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $109.29.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2019/02/11/insider-selling-celgene-co-celg-director-sells-23466-shares-of-stock.html.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Further Reading: How a Put Option Works
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.